Pharmacological approaches to cardio-renal syndrome: a role for the inodilator levosimendan
Clicks: 174
ID: 274425
2017
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Star Article
30.0
/100
174 views
28 readers
AI Quality Assessment
Not analyzed
Readership in this journal
StarRanked #3 of 291 articles by views in European heart journal supplements : journal of the European Society of Cardiology
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 291 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Pathological interplay between the heart and kidneys—also known as cardio-renal syndrome (CRS)—is frequently encountered in heart failure and is linked to worse prognosis and quality of life. Drug therapies for this complex situation may ...
Abstract Quality Issue:
This abstract appears to be incomplete or contains metadata (36 words).
Try re-searching for a better abstract.
| Reference Key |
matskeplishvili2017europeanpharmacological
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Francesco Fedele, Kristjan Karason, Simon Matskeplishvili;Francesco Fedele;Kristjan Karason;Simon Matskeplishvili; |
| Journal | European heart journal supplements : journal of the European Society of Cardiology |
| Year | 2017 |
| DOI |
10.1093/eurheartj/sux002
|
| URL | |
| Keywords |
|
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.